Growth Drivers and Key Restraints
Throat cancer can be described as the cancer of vocal cords, larynx, and other locations in the throat. The symptoms include a change in voice, cough, ear pain, sore throat, and issues in swallowing. Throat cancer comprises pharyngeal cancer and laryngeal cancer. Globally, in 2012, close to 157,000 cases of laryngeal cancer were diagnosed. In addition, the National Cancer Institute says that almost 1.1% of the adult population, at some point during their lifetime, is expected to be diagnosed with pharyngeal cancer and 0.4% with laryngeal cancer.
The primary causes of throat cancer include heavy alcohol consumption, smoking tobacco, chewing betel liquid, and HPV infection. The American cancer society suggests that in 2016, roughly 13,430 new cases were diagnosed with laryngeal cancer, affecting 79% of men and 21% of women.
With the surge in the smoking population in emerging countries and the expansion of the aging population, the market is presumed to have a profitable run during the review period. But, the lack of targeted drugs for treating throat cancer could debilitate the growth rate of the market in the subsequent years.
Industry Trends
Surge in Research and Development
Various researches with the aim of developing chemotherapies such as targeted therapies. EGFR inhibitors, as well as angiogenesis inhibitors, are used in these processes. At present, the use of transoral robotic surgeries is popular among the physicians for removing tumors owing to minimal invasion and fewer side effects. With respect to radiation therapy, numerous doctors are striving to destroy cancer cells by using proton beam therapy as this causes less tissue damage.